Clinical efficacy of two-phase leukocyte filtration in high-risk patients undergoing coronary revascularization with cardiopulmonary bypass

Journal of Extra-Corporeal Technology

Volumn 41, Issue 3, 2009, Pages 149-156

  Gunaydin, Serdar ^a   Modine, Thomas ^b   Sari, Tamer ^c   Zorlutuna, Yaman ^c   Gourlay, Terence ^d  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c BAYINDIR HOSPITAL   (Turkey)

^d UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Cardiopulmonary bypass; Leukapheresis; Leukocyte filtration; Reperfusion injury

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE MB; D DIMER; GELATINASE B; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CELL SEPARATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; FEMALE; FILTER; FOLLOW UP; HEART FUNCTION; HEART MUSCLE REVASCULARIZATION; HEART PERFUSION; HEART PRESERVATION; HIGH RISK PATIENT; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; MALE; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PROSPECTIVE STUDY; TWO PHASE LEUKOCYTE FILTRATION;

EID: 75149140128     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Asimakopoulos G, Gourlay T. A review of anti-inflammatory strategies in cardiac surgery. Perfusion. 2003;18(Suppl 1):7-12.
2. De Somer F. Optimization of the perfusion circuit and its possible impact on the inflammatory response. J Extra Corpor Technol. 2007;39:285-8.
3. Rimpilainen R, Biancari F, Wistbacka J, et al. Outcome after coronary artery bypass surgery with miniaturized versus conventional cardio-pulmonary bypass. Perfusion. 2008;23:361-7.
4. Gunaydin S, McCusker K, Vijay V. Strategic leukofiltration in cardiac surgery. Curr Med Chem Cardiovasc Hematol Agents. 2005;3: 323-31.
5. Matheis G, Scholz M, Simon A, Henrich D, Wimmer-Greinecker G, Moritz A. Timing of leukocyte filtration during cardiopulmonary bypass. Perfusion. 2001;16(Suppl):31-7.
6. Asimakopoulos G. The inflammatory response to CPB: The role of leukocyte filtration. Perfusion. 2002;17(Suppl):7-10.
7. Modine T, Azzaoui R, Ouk T, et al. Changes in cerebral vascular reactivity occur early during cardiopulmonary bypass in the rat. Ann Thorac Surg. 2006;82:672-8.
8. Gunaydin S, McCusker K, Vijay V, et al. Comparison of polymethoxy-ethylacrylate-coated circuits with leukocyte filtration and reduced heparinization protocol on heparin-bonded circuits in different risk cohorts. Perfusion. 2006;21:329-42.
9. Gunaydin S, Sari T, McCusker K, et al. Clinical evaluation of strategic leukofiltration with surface modification: Enhanced preservation or fantasy. Filtration. 2005;1:47-58.
10. Gunaydin S, McCusker K, Vijay V, et al. Clinical significance of strategic leukocyte filtration in different risk cohorts undergoing cardiac surgery. Filtration. 2005;1:95-106.
11. Day JR, Taylor KM. The systemic inflammatory response syndrome and cardiopulmonary bypass. Int J Surg. 2005;3:129-40.
12. Gourlay T, Fleming J, Taylor KM. Laboratory evaluation of the Pall LG6 leukocyte depleting arterial line filter. Perfusion. 1992;7: 131-40.
13. Fontes ML, Mathew JP, Rinder HM, Zelterman D, Smith BR, Rinder CS; Multicenter Study of Perioperative Ischemia. (McSPI) Research Group. Atrial fibrillation after cardiac surgery/cardiopulmonary bypass is associated with monocyte activation. Anesth Analg. 2005;101:17-23.
14. Gunaydin S, Ayrancioglu K, Dikmen E, et al. Clinical effects of leuko-filtration and surface modification on post-cardiopulmonary bypass atrial fibrillation in different risk cohorts. Perfusion. 2007;22:279-88.
15. Ogiwara M, Kyo S, Ohuchi H, et al. High pressure occlusion of leukocyte depletion arterial line filter in patients with cardio-pulmonary bypass surgery. Kyobu Geka. 2001;54:759-63.
16. Noh H, Fogler EA. Volumetric interpretation of protein adsorption: Competition from mixtures and the Vroman effect. Biomaterials. 2007;28:405-22.
17. Patel AN, Sutton SW, Livingston S, et al. Clinical benefits of leukocyte filtration during valve surgery. Am J Surg. 2003;186:636-9, discussion 639-40.
18. Whitaker DC, Stygall JA, Newman SP, Harrison MJ. The use of leucocyte-depleting and conventional arterial line filters in cardiac surgery: A systematic review of clinical studies. Perfusion. 2001; 16:433-46.
19. Leal-Noval SR, Amaya R, Herruzo A, et al. Effects of a leukocyte depleting arterial line filter on perioperative morbidity in patients undergoing cardiac surgery: A controlled randomized trial. Ann Thorac Surg. 2005;80:1394-400.
20. Scholz M, Simon A, Matheis G, et al. Leukocyte filtration fails to limit functional neutrophil activity during cardiac surgery. Inflamm Res. 2002;51:363-8.
21. Sahlman A, Ahonen J, Salo JA, Rämö OJ. No impact of a leucocyte depleting arterial line filter on patient recovery after cardiopulmonary bypass. Acta Anaesthesiol Scand. 2001;45:558-63.
22. Royston D, Kovesi T, Marczin N. The unwanted response to cardiac surgery: Time for a reappraisal? J Thorac Cardiovasc Surg. 2003;125: 32-5.
23. Landis RC, Arrowsmith JE, Baker RA, et al. Consensus statement: Defining minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypass. Heart Surg Forum. 2008;11: E316-22.